Slingshot members are tracking this event:
DBV Technologies (DBVT) Expects to Complete Phase III PEPITES Trial Evaluating Viaskin Peanut in Children with Peanut Allergies in 2H 2017
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Sep 07, 2017
- Following Another Phase 3 Study Initiation of Viaskin in Peanut Allergy, We Discuss the Data Released To Date. DBVT, AIMT Executed On: Sep 11, 2017 at 03:00 PM EDT
Related Keywords Phase Iii Pepites Trial, Viaskin Peanut, Children With Peanut Allergies, Trial Completion